Your session is about to expire
← Back to Search
GTX Chemoradiation for Pancreatic Cancer
Study Summary
This trial will study the safety and efficacy of a combination of Gemcitabine, Capecitabine, and Docetaxel in patients with locally advanced pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had chemotherapy or radiation therapy before.My disease is advanced but hasn't spread far, confirmed by a scan.My pancreatic cancer has been confirmed by a tissue test.I don't have health issues that prevent surgery, radiation, or chemo.Women who are not pregnant or going through menopause need to have a negative pregnancy test before starting the treatment.You do not have signs of cancer spreading to other parts of the body based on specific imaging tests.My tumor cannot be surgically removed because it is too close to major blood vessels.Your blood tests need to show certain levels of different types of blood cells and chemicals in your body.
- Group 1: Group I
- Group 2: Group II
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other ongoing trials that are testing the combination of Gemcitabine, capecitabine, and docetaxel before radiotherapy?
"As of right now, there are 1057 active studies for Gemcitabine, capecitabine, docetaxel followed by radiotherapy. Of these, 358 are in Phase 3. With several trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy running out of in Guangzhou, Guangdong, there are still a total of 53306 locations operating trials for Gemcitabine, capecitabine, docetaxel followed by radiotherapy."
Are there any spots still open in this research project?
"This study is not actively recruiting patients at this moment. The listing was originally created on December 1st, 2009 and was most recently edited on January 27th, 2014. If you are looking for other studies, 594 trials for cancer of the pancreas and 1057 for Gemcitabine, capecitabine, docetaxel followed by radiotherapy are still admitting patients."
What condition is the Gemcitabine, capecitabine, docetaxel followed by radiotherapy treatment most often used to improve?
"Gemcitabine, capecitabine, and docetaxel followed by radiotherapy is a common treatment for patients that have received adjuvant anthracycline-containing therapy. This treatment method is also effective for patients suffering from conditions such as head and soft tissue sarcoma, as well as colorectal carcinoma."
Share this study with friends
Copy Link
Messenger